Search by drug, manufacturer, or indication

Displaying 691 - 700 of 1165

Trintellix (vortioxetine)

Status:

Concluded with an LOI

Manufacturer:

Lundbeck Canada Inc.

Indication:

Major Depressive Disorder

Last updated December 3, 2020

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Renal Cell Carcinoma

Last updated December 1, 2020

Onpattro (patisiran)

Status:

Concluded with an LOI

Manufacturer:

Alnylam Netherlands B.V.

Indication:

Hereditary transthyretin-mediated amyloidosis

Last updated November 30, 2020

Verkazia (cyclosporine)

Status:

Concluded with an LOI

Manufacturer:

Santen Incorporated

Indication:

Severe Vernal Keratoconjunctivitis

Last updated November 20, 2020

Kadcyla (trastuzumab emtansine)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Early Breast Cancer

Last updated November 5, 2020

Libtayo (cemiplimab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Cutaneous Squamous Cell Carcinoma

Last updated November 4, 2020

Avsola (infliximab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and Ulcerative Colitis

Last updated November 2, 2020

Takhzyro (lanadelumab)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Hereditary Angioedema

Last updated October 30, 2020

Revestive (teduglutide)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Short Bowel Syndrome (SBS)

Last updated October 28, 2020

Cablivi (caplacizumab)

Status:

Negotiations were not pursued

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Last updated October 23, 2020